A Study of Daratumumab

NCT05438043 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Daratumumab
DRUG: Carfilzomib
DRUG: Dexamethasone
DRUG: Lenalidomide
DRUG: Pomalidomide

Sponsor

Janssen Research & Development, LLC